RCC Clinical Trials

52 recruitingLast updated: June 18, 2026

There are 52 actively recruiting rcc clinical trials across 31 countries. Studies span Phase 2, Phase 1, Not Applicable, Phase 3. Top locations include Rochester, Minnesota, United States, Boston, Massachusetts, United States, New York, New York, United States. Updated daily from ClinicalTrials.gov.


RCC Trials at a Glance

52 actively recruiting trials for rcc are listed on ClinicalTrialsFinder across 6 cities in 31 countries. The largest study group is Phase 2 with 22 trials, with the heaviest enrollment activity in Rochester, Boston, and New York. Lead sponsors running rcc studies include GI Innovation, Inc., Jinling Hospital, China, and University of Texas Southwestern Medical Center.

Browse rcc trials by phase

Treatments under study

About RCC Clinical Trials

Looking for clinical trials for RCC? There are currently 5 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new RCC trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about RCC clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 52 trials

Recruiting
Not Applicable

Investigation of Lymph Node Biology in Kidney Cancer

Renal Cell Carcinoma (RCC)
Yale University33 enrolled1 locationNCT07038733
Recruiting
Phase 1

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors

Colorectal, CancerEsophageal CancerGastric Cancer+9 more
Genentech, Inc.450 enrolled41 locationsNCT05581004
Recruiting
Phase 1

KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors

Non-small Cell Lung Cancer (NSCLC)Pancreatic Ductal Adenocarcinoma (PDAC)Colorectal Cancer (CRC)+4 more
Kura Oncology, Inc.300 enrolled38 locationsNCT06026410
Recruiting
Not Applicable

ClAmpless, Sutureless PartIAl Nephrectomy for Renal Masses

Renal Cell Carcinoma (RCC)
University of Florida59 enrolled1 locationNCT06722807
Recruiting
Phase 1

A Phase 1 Study of the Safety and Tolerability of CTX-10726

Endometrial CancerRenal Cell Carcinoma (RCC)Hepatocellular Carcinoma (HCC)+1 more
Compass Therapeutics70 enrolled5 locationsNCT07419841
Recruiting
Phase 1Phase 2

Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer

Metastatic Renal Cell CarcinomaCarcinoma, Renal CellAdvanced Renal Cell Carcinoma+10 more
Pfizer224 enrolled109 locationsNCT07227415
Recruiting
Phase 3

Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer

Renal Cell Carcinoma (RCC)Clear Cell Renal Cell CarcinomaStage II Renal Pelvis Cancer AJCC v8+1 more
Alliance for Clinical Trials in Oncology1,040 enrolled414 locationsNCT06661720
Recruiting
Phase 1

Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma

Renal Cell CarcinomaClear Cell Renal Cell CarcinomaKidney Cancers+6 more
Neomorph, Inc30 enrolled10 locationsNCT07300241
Recruiting
Phase 1

Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors

Head and Neck Squamous Cell Carcinoma (HNSCC)Non-small Cell Lung Cancer (NSCLC)Solid Tumor+7 more
Exelixis1,314 enrolled122 locationsNCT05176483
Recruiting
Phase 1Phase 2

A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Ipilimumab or Cabozantinib in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)

Advanced Renal Cell Carcinoma (RCC)
Bristol-Myers Squibb254 enrolled72 locationsNCT07293351
Recruiting
Phase 2

68Ga-NYM096 PET/ CT for the Detection of ccRCC in Presurgical Patients With Complex Cystic Renal Leision

ccRCCComplex Renal Cyst
Peking Union Medical College Hospital70 enrolled1 locationNCT06949215
Recruiting
Phase 1Phase 2

GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors

Cervical CancerUrothelial CarcinomaAdvanced Solid Tumor+3 more
GI Innovation, Inc.317 enrolled12 locationsNCT04977453
Recruiting
Not Applicable

18F-T2 PET/CT Imaging for CAIX Positive Solid Tumors

Breast CancerColorectal, CancerPancreatic Cancer+11 more
Peking University First Hospital200 enrolled1 locationNCT07557225
Recruiting
Phase 2

Perioperative Trial With IO/TKI for Multi-stage Clear Cell Renal Cell Carcinoma

Clear Cell RCC
Jinling Hospital, China75 enrolled1 locationNCT07571551
Recruiting
Phase 2

Phase 2 Study for the Patient, Who Has Diagnosed With Small Cell Lung Cancer (SCLC) or Non Small Cell Lung Cancer (NSCLC) or Renal Cell Carcinoma (RCC) and Finished the First Line Stand Treatment , Need More Treatment

Renal Cell Carcinoma (RCC)Small Cell Lung CancerNon-Small-Cell Lung
Advenchen Pharmaceuticals, LLC.80 enrolled7 locationsNCT05363280
Recruiting
Phase 2

A Randomized Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC)

Clear-Cell Renal-Cell Carcinoma (ccRCC)Metastatic Renal Cell Carcinoma (mRCC)Advanced Renal Cell Carcinoma (aRCC)
Brian Rini120 enrolled1 locationNCT07188896
Recruiting
Phase 1Phase 2

A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body

MelanomaAdvanced Solid TumorsClear-Cell Renal-Cell Carcinoma (ccRCC)
Regeneron Pharmaceuticals240 enrolled11 locationsNCT06413680
Recruiting

Validation of RCC Predicting Model With Emulated-target Trial

Prognostic Cancer ModelRenal Cell Carcinoma (RCC)Prognosis+4 more
Peking University Third Hospital4,700 enrolled1 locationNCT07117227
Recruiting
Phase 1Phase 2

Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell Carcinoma (pRCC)

Advanced Clear Cell Renal Carcinoma (Ccrcc)Papillary Renal Cell Carcinoma (Prcc)
National Cancer Institute (NCI)100 enrolled1 locationNCT05665361
Recruiting
Not Applicable

CBCT Guided Markerless SBRT for Renal Cell Cancer

Renal Cell Carcinoma (RCC)
Erasmus Medical Center40 enrolled1 locationNCT07402109